Home > Riviste > Minerva Surgery > Fascicoli precedenti > Minerva Surgery 2023 October;78(5) > Minerva Surgery 2023 October;78(5):510-7



Opzioni di pubblicazione
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo



Minerva Surgery 2023 October;78(5):510-7

DOI: 10.23736/S2724-5691.23.09872-6


lingua: Inglese

Neoadjuvant systemic treatment in breast cancer surgery: is it always worth it?

Pasquale LOSURDO 1 , Margherita FEZZI 1, Fabiola GIUDICI 1, Livia BRESSAN 1, Serena SCOMERSI 1, Rita CECCHERINI 2, Fabrizio ZANCONATI 3, Marina BORTUL 1

1 Breast Unit, Division of General Surgery, Department of Medical and Surgical Sciences, Hospital of Cattinara, University of Trieste, Trieste, Italy; 2 Breast Unit, Breast and Female Reproductive System Oncology (OSARF), AOU Giuliano Isontina, Cattinara Hospital, Trieste, Italy; 3 Breast Unit, Division of Pathology, Department of Medical and Surgical Sciences, Hospital of Cattinara, University of Trieste, Trieste, Italy

BACKGROUND: Surgeons perspective of breast cancer (BC) treatment has deeply changed in recent time. We investigated survival outcomes of BC patients who underwent Neoadjuvant systemic treatment (NAT) before surgery and to assess the role of NAT in determining possible prognosis.
METHODS: We retrospectively analyzed a total of 2372 BC patients consecutively enrolled in our prospective institutional database. Seventy-eight patients over 2372 reached the inclusion criteria and underwent surgery after NAT.
RESULTS: After NAT, the 50% of luminal-B-HER2+ and the 53% of HER2+ had a pathological complete response (pCR) and only 18.5% of the TNs had a pCR. NAT significantly changed lymph node status (P=0.05). All women with pCR are still alive (No-pCR 0.732 CI: 0.589-0.832; yes-pCR 1.000 CI: 1.00-1.00; P=0.02). The molecular biology of the tumor, after NAT, is strictly related to survival both for 3- and 5-years OS. A triple negative BC have the worst prognosis (HER2+ 0.796 CI: 0.614-1; Luminal-A: 1 CI:1-1; LuminalB-HER2 -: 0.801 CI: 0.659-0975; LuminalB-HER2+: 1 CI:1-1; TN 0.542 CI: 0.372-0789, P=0.002).
CONCLUSIONS: We can state that, based on our experience, we can consider safe and effective conservative interventions following neoadjuvant therapy. An adequate selection of patients is crucial. It is also clear how the planning of the therapeutic path plays a key role in an interdisciplinary context. NAT is a source of hope for the future both for the identification of new predictors of prognosis and in the field of research, for the development of new drugs.

KEY WORDS: Breast neoplasms; Neoadjuvant therapy; Surgery

inizio pagina